On November 7th, the Information Office of the Guangzhou Municipal People's Government held a press conference on the 3rd Guangdong Hong Kong Macao Greater Bay Area Health Cooperation Conference. At the meeting, Mou Zhiping, Executive Deputy Director of the Dawan District Office and Deputy Director of the Municipal Development and Reform Commission of Guangzhou, introduced the development situation and future development ideas of the biopharmaceutical industry in Guangzhou.

Mou Zhiping introduced that in recent years, the Guangzhou Municipal Party Committee and Government have deeply implemented the "Outline of the Development Plan for the Guangdong Hong Kong Macao Greater Bay Area", attached great importance to the development of strategic emerging industries in biopharmaceuticals, and vigorously promoted the integration, clustering, and ecological development of industries. Industrial clusters have been awarded incentives and commendations by the State Council for three consecutive years from 2018 to 2020, and were awarded excellent awards in the first batch of national strategic emerging industry clusters evaluation in 2023, Ranked among the top tier of the country in terms of development level.

Mou Zhiping believes that the high-quality development of Guangzhou's biopharmaceutical industry has made significant progress in the following three aspects. Firstly, the scale of industrial development continues to grow. In 2022, the added value of the biopharmaceutical and health industry in Guangzhou was 165.147 billion yuan, accounting for 5.73% of GDP, with a year-on-year increase of 8.5%; In the first three quarters of this year, the added value reached 124.182 billion yuan. There are over 6400 biopharmaceutical enterprises of various types, including 12 Fortune Global 500 enterprises, 139 above designated enterprises, and 54 listed enterprises. The second is the continuous improvement of the industrial policy system. In recent years, a series of policy measures have been introduced, including the "Several Regulations on Accelerating the Development of the Biomedical Industry in Guangzhou (Revised)" and the "Implementation Plan for Accelerating the Development of Medical Laboratory Industry Clusters in Guangzhou", to support Guangzhou's formation of certain advantages in sub fields such as antibody drugs, nucleic acid drugs, modern Chinese medicine, high-end medical devices, gene editing, and stem cell therapy. The third is the continuous enhancement of industrial innovation capabilities. Strategic scientific and technological forces such as the Guangzhou Laboratory, the Human Cell Genealogy Large Science Facility, and the International Large Science Program for Human Proteome Navigation are accelerating their construction, all located in the International Biological Island Park. There are currently 217 innovation related platforms in the biopharmaceutical industry. In the first three quarters of this year, the city has obtained 81 new drug approvals, of which 60 are Class I new drugs. Forming a multi-level talent team led by Nobel laureates, academicians of the Chinese Academy of Sciences and the Chinese Academy of Sciences, and industry leaders.

Looking forward to the future, Mou Zhiping stated that the next step is for Guangzhou to be based in the Bay Area and face the world, focusing on major regions, key areas, and key links, highlighting reform leadership, innovation leadership, and openness leadership, strengthening top-level design, innovation leadership breakthroughs, innovation resource aggregation, building an industrial ecosystem, and adhering to high-level opening-up. Guangzhou will coordinate the planning and layout of industrial parks throughout the city, and coordinate policy resources throughout the city, Continuously deepen cooperation between Hong Kong and Macao, vigorously promote the innovative development, agglomeration development, ecological development, and international development of Guangzhou's biopharmaceutical industry, and strive to create a global highland for biopharmaceutical innovation and industrial development. One is to accelerate the research and development of the "1+N" policy system. We are researching and formulating several policy measures to promote the high-quality development of the biopharmaceutical industry in Guangzhou. We are currently publicly soliciting opinions on the official website. Friends from all walks of life are invited to continue to pay attention and provide valuable opinions. We will accelerate the implementation of necessary procedures, publish and implement them as soon as possible, and enable enterprises to benefit as soon as possible. At the same time, we will accelerate the research and development of special implementation plans and construct N supporting measures for specific matters such as research-oriented hospitals and major innovative pharmaceutical equipment product catalogs. The second is to systematically plan the "one island, multiple parks" park planning. Focus on optimizing and enhancing the core spatial layout of the international biological island, create a "one island, multiple parks" policy pilot zone with the international biological island as the park brand, and create the latest landmark industrial cluster in the city. The third is to further improve the industrial development ecology. Actively hosting the 16th China Bioindustry Conference in 2024. Support influential leading enterprises to lead the formation of innovation consortia, accelerate the research and development, industrialization, and clinical application iteration of innovative drugs and high-end medical devices.